Every one of those 1 sits in a single category, market-trends. Medical Aesthetics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Intraocular Lenses
Every one of those 1 sits in a single category, market-trends. Medical Aesthetics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window. At 5, the average consequence score sits below the same-window beat average of 5.9. We currently track 1 Healthcare story that mention Intraocular Lenses, all published on March 21, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Intraocular Lenses. Shared-story counts are live from our verified record — not editorial picks.
Shanghai Haohai Biological Technology Co., Ltd. has reported a retreat in its full-year net income, reflecting the intensifying impact of China's centralized procurement policies. The decline underscores the challenges facing domestic medtech leaders as they navigate margin compression in ophthalmology and heightened competition in the medical aesthetics market.